Table 2.
Characteristics of non-atrial fibrillation patients by drug exposure: dabigatran propensity score 1:1 match. Values are numbers (percentages) unless stated otherwise
| Characteristics | Full cohort | Propensity matched cohort | |||||
|---|---|---|---|---|---|---|---|
| Dabigatran (n=732) | Warfarin (n=45 198) | P value | Dabigatran (n=732) | Warfarin (n=732) | P value | ||
| Demographics and risk scores | |||||||
| Mean (SD) age, years | 64.6 (12.9) | 61.9 (13.7) | <0.01 | 64.6 (12.9) | 63.1 (14.1) | <0.01 | |
| Age, years: | <0.01 | 0.54 | |||||
| 18-64 | 358 (48.9) | 24 172 (53.5) | 358 (48.9) | 369 (50.4) | |||
| 65-75 | 202 (27.6) | 13 445 (29.7) | 202 (27.6) | 202 (27.6) | |||
| ≥76 | 172 (23.5) | 7581 (16.8) | 172 (23.5) | 161 (22.0) | |||
| Female | 272 (37.2) | 23 500 (52.0) | <0.01 | 272 (37.2) | 269 (36.7) | 0.81 | |
| Race/ethnicity: | <0.01 | 0.42 | |||||
| White | 499 (68.2) | 33 907 (75.0) | 499 (68.2) | 521 (71.2) | |||
| Black | 82 (11.2) | 5343 (11.8) | 82 (11.2) | 72 (9.8) | |||
| Other | 151 (20.6) | 5948 (13.2) | 151 (20.6) | 139 (19.0) | |||
| Charlson-Deyo index: | 0.30 | 0.38 | |||||
| 0-1 | 413 (56.4) | 26 370 (58.3) | 413 (56.4) | 425 (58.1) | |||
| ≥2 | 319 (43.6) | 18 828 (41.7) | 319 (43.6) | 307 (41.9) | |||
| HAS-BLED score: | 0.17 | 0.32 | |||||
| 0-2 | 564 (77.0) | 33 857 (74.9) | 564 (77.0) | 578 (79.0) | |||
| 3 | 118 (16.1) | 8501 (18.8) | 118 (16.1) | 114 (15.6) | |||
| ≥4 | 50 (6.8) | 2840 (6.3) | 50 (6.8) | 40 (5.5) | |||
| Baseline comorbidities | |||||||
| Myocardial infarction | 69 (9.4) | 2492 (5.5) | <0.01 | 69 (9.4) | 78 (10.7) | 0.37 | |
| CABG/PCI | 35 (4.8) | 1004 (2.2) | <0.01 | 35 (4.8) | 43 (5.9) | 0.29 | |
| Congestive heart failure | 141 (19.3) | 4635 (10.3) | <0.01 | 141 (19.3) | 147 (20.1) | 0.61 | |
| Diabetes | 209 (28.6) | 10 322 (22.8) | <0.01 | 209 (28.6) | 190 (26.0) | 0.15 | |
| History of gastrointestinal bleed: | 3 (0.4) | 499 (1.1) | 0.07 | 3 (0.4) | 8 (1.1) | 0.10 | |
| Upper gastrointestinal bleed | 3 (0.4) | 316 (0.7) | 0.35 | 3 (0.4) | 7 (1.0) | 0.16 | |
| Lower gastrointestinal bleed | 0 (0.0) | 183 (0.4) | 0.08 | 0 (0.0) | 1 (0.1) | – | |
| Helicobacter pylori | 2 (0.3) | 194 (0.4) | 0.52 | 2 (0.3) | 1 (0.1) | 0.56 | |
| Diverticulosis | 52 (7.1) | 3645 (8.1) | 0.34 | 52 (7.1) | 35 (4.8) | 0.05 | |
| Renal disease | 49 (6.7) | 3742 (8.3) | 0.12 | 49 (6.7) | 44 (6.0) | 0.56 | |
| Concomitant drug exposure | |||||||
| Inhibitors of warfarin* | 457 (62.4) | 24 591 (54.4) | <0.01 | 457 (62.4) | 461 (63.0) | 0.73 | |
| Inducers of warfarin* | 205 (28.0) | 15 192 (33.6) | <0.01 | 205 (28.0) | 196 (26.8) | 0.49 | |
| Antiplatelet agents | 128 (17.5) | 3418 (7.6) | <0.01 | 128 (17.5) | 137 (18.7) | 0.44 | |
| Non-steroidal anti-inflammatory drugs | 162 (22.1) | 16 408 (36.3) | <0.01 | 162 (22.1) | 159 (21.7) | 0.79 | |
| Selective serotonin reuptake inhibitors | 118 (16.1) | 9002 (19.9) | 0.01 | 118 (16.1) | 127 (17.3) | 0.41 | |
| Proton pump inhibitors | 165 (22.5) | 11 290 (25.0) | 0.13 | 165 (22.5) | 159 (21.7) | 0.64 | |
| Glucocorticoids | 130 (17.8) | 11 377 (25.2) | <0.01 | 130 (17.8) | 125 (17.1) | 0.66 | |
Before propensity score match: continuous data compared using t test and categorical variable using χ2 test.
After propensity score match: continuous data compared using paired t test and McNemar’s test.
CABG/PCI= coronary bypass graft/percutaneous intervention.
*See appendix (table A2).